Screener
Alnylam Pharmaceuticals ALNY Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets | 183,359 | 194,916 |
| Deferred tax assets | 113,792 | 125,975 |
| Restricted investments | 22,171 | 22,170 |
| Other assets | 65,132 | 59,461 |
| Total assets | $5,558,769 | $4,966,331 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $108,016 | $115,721 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's other non-current assets?
- Alnylam Pharmaceuticals (ALNY) reported other non-current assets of $65.13M in Q2 2026.
- How has Alnylam Pharmaceuticals's other non-current assets changed year-over-year?
- Alnylam Pharmaceuticals's other non-current assets increased by 13.9% year-over-year, from $57.17M to $65.13M.
- What is the long-term trend for Alnylam Pharmaceuticals's other non-current assets?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's other non-current assets has grown at a 5.7% compound annual growth rate (CAGR), from $45.05M to $59.46M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Alnylam Pharmaceuticals's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude